Contributions
Abstract: EP1445
Type: ePoster
Abstract Category: Clinical aspects of MS - 11 Comorbidity
Background: Weight loss diets are primary recommended treatments for metabolic disease and are often associated with improved sleep. Both sleep and metabolic disorders are overrepresented in people with multiple sclerosis (MS); however, whether weight loss diets are associated with improvements in sleep quality in this vulnerable population is unknown.
Methods: We conducted a controlled feeding study of different calorie restriction diets in 36 people with MS for a period of 8 weeks. Energy expenditure was determined using indirect calorimetry, and patients were randomized to receive 1 of 3 diets: a continuous calorie restriction diet (22% daily reduction in energy needs), an intermittent calorie restriction diet (75% reduction in calorie needs 2 days/week; 100% of daily needs 5 days/week), and a weight-stable diet (100% of daily calorie needs). At baseline and at week 8, participants provided information on sleep by completing the Pittsburgh Quality Sleep Index (PSQI), from which a global sleep quality score was calculated.
Results: Of the 36 patients enrolled, 31(86%) completed the trial. Participants randomized to calorie restriction diets lost an average of 7.3(SD: 4.6) lbs over 8 weeks; changes in weight did not differ by type of calorie restriction diet (P=0.12). At baseline, participants had median PSQI scores of 7 (interquartile range [IQR]: 3.5 to 8.5) and 19 (53%) participants reported scores indicative of poor sleep quality. Weight loss was marginally correlated with improvements in sleep quality score (r= -0.32; P=0.06). Individuals in the top quartile of weight loss - corresponding to a ³8.2lb weight loss - experienced an average 3.99 point improvement in global sleep quality score when compared to individuals in the lowest quartile of weight loss- corresponding to a < 3lb weight loss (quartile 4 vs. quartile 1 mean reduction in PSQI score=3.99; 95% CI: 0.58-7.39; P=0.03). Changes in sleep quality did not differ between weight loss diets.
Conclusions: This preliminary study suggests that among people with MS, weight loss is associated with improved sleep quality. Subsequent results will assess effects of weight loss diets on changes in fatigue levels.
Disclosure:
Diane Vizthum: nothing to disclose
Bobbie Henry Barron: nothing to disclose
David Baer: nothing to disclose
Patrick Sullivan: nothing to disclose
Ellen Mowry receives research funding from the National MS Society (RG4407A2, Harry Weaver Award) and Department of Defense. Teva Neuroscience provides free glatiramer acetate for the investigator-initiated vitamin D trial, of which she is the am PI. She is also the PI of investigator-initiated studies funded by Biogen, Sanofi-Genzyme. She is also a site investigator of trials sponsored by Sun Pharma, Biogen and receives royalties from Up to Date.
Abstract: EP1445
Type: ePoster
Abstract Category: Clinical aspects of MS - 11 Comorbidity
Background: Weight loss diets are primary recommended treatments for metabolic disease and are often associated with improved sleep. Both sleep and metabolic disorders are overrepresented in people with multiple sclerosis (MS); however, whether weight loss diets are associated with improvements in sleep quality in this vulnerable population is unknown.
Methods: We conducted a controlled feeding study of different calorie restriction diets in 36 people with MS for a period of 8 weeks. Energy expenditure was determined using indirect calorimetry, and patients were randomized to receive 1 of 3 diets: a continuous calorie restriction diet (22% daily reduction in energy needs), an intermittent calorie restriction diet (75% reduction in calorie needs 2 days/week; 100% of daily needs 5 days/week), and a weight-stable diet (100% of daily calorie needs). At baseline and at week 8, participants provided information on sleep by completing the Pittsburgh Quality Sleep Index (PSQI), from which a global sleep quality score was calculated.
Results: Of the 36 patients enrolled, 31(86%) completed the trial. Participants randomized to calorie restriction diets lost an average of 7.3(SD: 4.6) lbs over 8 weeks; changes in weight did not differ by type of calorie restriction diet (P=0.12). At baseline, participants had median PSQI scores of 7 (interquartile range [IQR]: 3.5 to 8.5) and 19 (53%) participants reported scores indicative of poor sleep quality. Weight loss was marginally correlated with improvements in sleep quality score (r= -0.32; P=0.06). Individuals in the top quartile of weight loss - corresponding to a ³8.2lb weight loss - experienced an average 3.99 point improvement in global sleep quality score when compared to individuals in the lowest quartile of weight loss- corresponding to a < 3lb weight loss (quartile 4 vs. quartile 1 mean reduction in PSQI score=3.99; 95% CI: 0.58-7.39; P=0.03). Changes in sleep quality did not differ between weight loss diets.
Conclusions: This preliminary study suggests that among people with MS, weight loss is associated with improved sleep quality. Subsequent results will assess effects of weight loss diets on changes in fatigue levels.
Disclosure:
Diane Vizthum: nothing to disclose
Bobbie Henry Barron: nothing to disclose
David Baer: nothing to disclose
Patrick Sullivan: nothing to disclose
Ellen Mowry receives research funding from the National MS Society (RG4407A2, Harry Weaver Award) and Department of Defense. Teva Neuroscience provides free glatiramer acetate for the investigator-initiated vitamin D trial, of which she is the am PI. She is also the PI of investigator-initiated studies funded by Biogen, Sanofi-Genzyme. She is also a site investigator of trials sponsored by Sun Pharma, Biogen and receives royalties from Up to Date.